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Hematopoietic cell transplantation (HCT) is a therapy option for aggressive forms of 
hematopoietic malignancies that are resistant to standard antitumoral therapies. 
Hematoablative treatment preceding HCT, however, opens a “window of opportunity” 
for latent Cytomegalovirus (CMV) by releasing it from immune control with the conse-
quence of reactivation of productive viral gene expression and recurrence of infectious 
virus. A “window of opportunity” for the virus represents a “window of risk” for the 
patient. In the interim between HCT and reconstitution of antiviral immunity, primarily 
mediated by CD8+ T cells, initially low amounts of reactivated virus can expand expo-
nentially, disseminate to essentially all organs, and cause multiple organ CMV disease, 
with interstitial pneumonia (CMV-IP) representing the most severe clinical manifestation. 
Here, I will review predictions originally made in the mouse model of experimental HCT 
and murine CMV infection, some of which have already paved the way to translational 
preclinical research and promising clinical trials of a preemptive cytoimmunotherapy of 
human CMV disease. Specifically, the mouse model has been pivotal in providing “proof 
of concept” for preventing CMV disease after HCT by adoptive transfer of preselected, 
virus epitope-specific effector and memory CD8+ T cells bridging the critical interim. 
However, CMV is not a “passive antigen” but is a pathogen that actively interferes with 
the reconstitution of protective immunity by infecting bone marrow (BM) stromal cells that 
otherwise form niches for hematopoiesis by providing the structural microenvironment 
and by producing hematopoietically active cytokines, the hemopoietins. Depending on 
the precise conditions of HCT, reduced homing of transplanted hematopoietic stem- 
and progenitor cells to infected BM stroma and impaired colony growth and lineage 
differentiation can lead to “graft failure.” In consequence, uncontrolled virus spread 
causes morbidity and mortality. In the race between viral BM pathology and reconstitu-
tion of antiviral immunity following HCT, exogenous reconstitution of virus-specific CD8+ 
T cells by adoptive cell transfer as an interventional strategy can turn the balance toward 
control of CMV.
Keywords: adoptive cell transfer, bone marrow stroma, CD8 T cells, Cytomegalovirus, hematopoietic cell 
transplantation, hemopoietins, immunotherapy, reconstitution
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CLiNiCAL iMPACT OF 
CYTOMeGALOviRUS iNFeCTiON
Human Cytomegalovirus (hCMV) is the prototype member of the 
subfamily Betaherpesvirinae of the Herpesviridae [reviewed in Ref. (1)]. 
Productive primary infection of adult, immunocompetent individuals 
is efficiently controlled by innate and adaptive immune recognition, 
so that the infection usually goes unnoticed or, in the worst case, with 
mild and unspecific symptoms of an infectious mononucleosis-like 
manifestation rarely diagnosed as a manifestation of hCMV infec-
tion [reviewed in Ref. (2)]. While virus replication is terminated 
and viral histopathology leading to overt organ disease is prevented, 
replication-competent hCMV genomes persist for the lifetime of the 
host in cells of the myeloid hematopoietic lineage, and presumably also 
in endothelial cells, in a non-productive state referred to as “latency.” 
Presence of hCMV-specific antibodies, so-called CMV “seropositivity,” 
is indicative of latent hCMV infection of otherwise healthy individuals. 
The establishment of latency is a feature common to herpesviruses. 
By definition, “latency” is characterized by the absence of infectious 
virions, but competence to reactivate (3). As reviewed recently by 
Poole and Sinclair under the figurative title “Sleepless Latency of 
Human Cytomegalovirus” (4), latency does not imply a genome-wide 
transcriptional quiescence; instead, the expression of a limited set 
of latency-associated microRNAs, coding transcripts, and proteins 
manipulates host cell functions [for further reviews, see Ref. (5, 6)].
Interest in hCMV as a medically relevant human pathogen is 
based on severe multiple organ disease that infection can cause in 
the immunocompromised host, including congenital hCMV infec-
tion of the embryo/fetus, which, after the advent of vaccination 
against Rubella, has become the most frequent viral cause of birth 
defects [reviewed in Ref. (7, 8)]. Besides patients with hereditary or 
acquired immunodeficiencies and patients with sepsis-associated 
immunosuppression, patients with iatrogenic immunosuppression 
are a major risk group at all medical centers. This includes recipi-
ents of solid organ transplantation (SOT) and of hematopoietic cell 
(HC) transplantation (HCT), in which latent virus can reactivate 
to productive infection under the conditions of therapy-inherent 
immunosuppression. In SOT, ischemia/reperfusion injury and 
prophylaxis against graft rejection (host-versus-graft reaction) 
can trigger and/or facilitate virus reactivation (9, 10). In HCT, 
hemato-/immunoablation, prophylaxis against graft-versus-host 
disease (GvHD) in case of allo-HCT, and also the underlying 
hematopoietic malignancy itself can trigger and/or facilitate virus 
reactivation. Reactivation can occur within the transplant in case 
of a latently infected, “seropositive” donor (D+) or in the organs of a 
latently infected, “seropositive” recipient (R+) or in both (D+R+) [for 
a synopsis of clinical aspects of CMV diseases, see Ref. (2, 11, 12)].
wHY A MOUSe MODeL? vALiDiTY OF 
MODeLS, PReDiCTive vALUe, AND 
LiMiTATiONS OF MODeLS TO KeeP  
iN MiND
Research on hCMV in human cells and tissues is limited to cell 
and organ culture models, observational clinical studies, biopsy 
and autopsy specimens, and, more recently, humanized mouse 
models with human tissue implants. For studying in vivo patho-
genesis, the humanized mouse models are closest to human CMV 
disease and are undoubtedly instrumental [for a review, see Ref. 
(13)], but they also have limitations to keep in mind. As a more 
technical aspect, these models are demanding in terms of reach-
ing statistical significance; yet, this can be solved by investment 
of resources. More critically, cytokine communication across cells 
from different species can be disturbed, virus spread is limited 
to take place between hematopoietic lineage cells and tissue 
implants while spread throughout the organism is interrupted, 
and disease cannot be studied in the context of the entirety of 
functional organs. This makes it impossible to study, for instance, 
survival benefit from antiviral therapies.
The strict host species-specificity of CMVs prevents study-
ing hCMV in animal models (14–16). In the author’s personal 
view, this is not a disadvantage. CMVs have co-speciated with 
their respective hosts, and each CMV species has evolutionarily 
acquired a set of “private” genes, not shared with other CMV 
species, to specifically adapt to its host [reviewed in Ref. (1, 17)]. 
This co-speciation is associated with “biological convergence.” 
This means that different CMV species have evolved similar 
host adaptations, although arriving there by different genes and 
mechanisms. As a prominent example, all CMVs have evolved 
genes to subvert immune recognition by interfering with the cell 
surface presentation of antigenic peptide-loaded MHC molecules 
for T-cell recognition or by downregulating or expressing ligands 
of activatory and inhibitory natural killer (NK) cell receptors, 
respectively [for reviews, see Ref. (18–20)]. Thus, even if it were 
possible, it would make no sense to study heterologous CMV–
host infections.
Most frequently used animal models are the mouse model in 
all its genetical variations, the guinea pig model with its advantage 
in addressing congenital infection [reviewed in Ref. (21)], and 
the rat model with its advantage in studying SOT and vascular 
diseases [reviewed in Ref. (22)]. Non-human primate models are 
considered closest to hCMV infection of humans [for a review, see 
Ref. (23)]. However, these models are demanding in many obvi-
ous aspects, and manipulation of host genetics as a tool of analysis 
is not a realistic option, unlike in the mouse model where inbred 
strains exist and where a host of transgenic/knock-in/knock-out 
strains are already available or can be made with relative ease [for 
a review, see Ref. (24)]. Furthermore, even non-human primate 
CMVs can critically differ genetically and phenotypically from 
hCMV (1, 23). Most importantly, one can provocatively state 
that “hCMV is not a model for hCMV,” as different strains of 
hCMV, in particular cell culture-adapted “laboratory strains” 
like AD169 as opposed to direct isolates from clinical samples, 
can differ substantially in their cell tropism and pathogenetical 
potential [discussed in Ref. (25)]. In fact, in terms of broad cell 
tropism, replicative potential, and in vivo pathogenicity, murine 
CMV (mCMV) is phenotypically closer to “clinical” isolates of 
hCMV than is hCMV strain AD169 on which hCMV research 
was focused for a long time.
Nonetheless, in the author’s view, mouse models must be 
carefully planned to appromixate a clinical correlate as close 
as feasible, and they receive their legitimation by addressing 
questions that cannot be addressed, or at least not easily be 
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addressed, by clinical investigation. I leave it without referenc-
ing that many published mouse models do not comply with this 
aim and remain artificial. Immunotherapy of CMV disease by 
adoptive transfer of viral epitope-specific CD8+ T cells, however, 
is a success story in that early predictions from the mouse model 
[ (26–28), reviewed in Ref. (29, 30)] have proven valid in clinical 
trials [ (31–36), reviewed in Ref. (12)] and have thus survived 
the “test of time.” Another prediction made by the mouse model 
has been a preeminent antigenicity, immunogenicity, and 
protection-inducing capacity of immediate-early (IE) proteins, 
in particular of major IE (MIE) protein IE1 [(37–40), reviewed 
in Ref. (18)] that is expressed under the control of a strong 
MIE promoter–enhancer element (41). Later, the IE1 epitope 
of mCMV was found to be expressed during viral latency for 
sensing by patrolling CD8+ T cells [(42–44), reviewed in Ref. 
(45)] and was the first epitope to be identified as an inducer of 
“memory inflation” during viral latency [(46, 47), reviewed in 
Ref. (48, 49)]. Although human CD8+ T-cell responses against 
IE1 of hCMV were reported soon thereafter (50), the prediction 
by the mouse model was long neglected, as the human immune 
response to hCMV was found to be dominated instead by 
epitopes of the virion tegument protein pUL83/pp65 (51, 52). 
This difference has been used for some time to question the 
validity of the mouse model. We know today that clonal selec-
tion in cell culture by pUL83/pp65 abundantly present in dense 
body-rich virus preparations (53) used for T-cell restimulation 
had selected against IE-specific T cells. With the advent of direct 
quantitation of epitope-specific T cells using peptide libraries 
or MHC–peptide multimers, the MIE locus was recognized 
as a coding hot spot for antigenicity and immunogenicity 
also in hCMV infection (54–56). More recently, as a further 
approximation of the model to its clinical correlate, cytoim-
munotherapy using human T cells, virus epitope-specific lines 
as well as human TCR-transduced cells, has been documented 
in HLA-transgenic mice infected with an antigenically “human-
ized” recombinant mCMV encoding an hCMV epitope. This 
approach allowed studying the resolution of organ infection and 
the demonstration of survival benefit (57).
All in all, with critical awareness of the genetic differences in 
both virus and host, the mouse model can make valuable predic-
tions and define questions for an aimed subsequent evaluation in 
other models as well as by clinical investigation.
iNTeRFeReNCe OF CMv iNFeCTiON 
wiTH T-CeLL ReCONSTiTUTiON  
AFTeR HCT
Lethality of CMv infection Post-HCT  
is Determined by the Degree of 
Hematoablation and the Number of 
Transplanted HC
Clinical manifestations of CMV infection are difficult to predict 
even when infection is diagnosed by routine quantitative PCR 
screening. Nevertheless, virus replication indirectly defined by 
viral load in terms of genome copy numbers has positive predic-
tive value for CMV disease [for a discussion of load thresholds 
for initiating therapy, see Ref. (58)]. As CMV disease is typically 
linked to an immunocompromised state, it is not far to seek that 
the degree of hemato-/immunoablation of the HCT recipient and 
the efficiency of hematopoietic reconstitution by donor HC are 
determinants of viral load, morbidity, and mortality. Obviously, 
this cannot be verified experimentally in HCT patients and 
would be logistically highly demanding to test in non-human 
primate models. We have therefore used the mouse model of 
HCT and infection with the Smith strain of mCMV [reviewed 
in Ref. (59)] to determine lethality of mCMV as a function of 
two variables, the dose of total-body γ-irradiation defining the 
degree of hemato-/immunoablation of the recipient and the 
number of transplanted HC defining the degree of hematopoietic 
reconstitution (Figure 1). The results document impressively that 
viral lethality can vary, depending on just these two parameters, 
between 0 and 100%. Comparison of the survival plots between 
HCT in the absence and presence of mCMV infection (Figure 1, 
left and right panel, respectively) documents a clear shift to over-
all higher mortality rates caused by the infection. These data also 
show that the Smith strain of mCMV is not replicatively attenu-
ated but can cause lethal disease if host immune control fails. 
Previous work on the histopathology has shown that mortality 
from mCMV in the experimental HCT model results from direct 
viral cytopathogenicity, and not from immunopathogenicity, in 
multiple organs (60, 61).
Lethality determined by these two variables is still a reduc-
tionistic approach, as in clinical reality many more parameters 
contribute to determining the outcome. These include donor and 
host genetics, time and site of virus reactivation, virus reactiva-
tion incidence defining the effective virus dose, difference in virus 
strains, toxicity of a preceding cytostatic leukemia therapy, GvHD 
prophylaxis, and antiviral drug therapy with myelosuppressive 
and nephrotoxic side effects. As a consequence, the clinical out-
come is “individual fate” and very difficult to predict.
CMv infects Bone Marrow Stroma Cells 
and inhibits Myelopoiesis in Cell Culture
Murine bone marrow (BM) stromal cells in primary cell culture 
are positive for alkaline phosphatase, while being negative for 
acidic phosphatase. They not only share properties with fibro-
blastic cells, such as the expression of fibronectin, but also express 
vimentin shared by mesenchymal cells, including fibroblasts, 
endothelial cells, and smooth muscle cells, as well as desmin, 
relating them to smooth muscle cells as well. Notably, they resem-
ble myofibroblastic cells in that they express α-smooth muscle 
actin (α-SMA), but simultaneously also show characteristics of 
endothelial cells by expressing von Willebrand factor (vWF) in 
Weibel–Palade bodies (Figure 2A, illustrating co-expression of 
α-SMA and vWF in large, flattened BM-derived stromal cells). 
Cell surface phenotyping (not comprehensive) revealed expres-
sion of MHC-I but not MHC-II, CD4 but not CD3 or CD8, 
macrophage-associated molecules Mac2 and CD11b but not 
Mac3, and expression of CD44 and CD71 (59). This phenotype 
indicates a multilineage progenitor nature of the BM stromal cells 
[reviewed in Ref. (62)]. Importantly, these cells are susceptible 
to productive mCMV infection and show the cytopathic effect 
FiGURe 1 | Negative impact of CMv infection on survival rates after HCT demonstrated in the murine model. (Top) Sketch of the experimental model, 
transplanting increasing numbers of hematopoietic cells (HC) to BALB/c recipients immunocompromised by hematoablative total-body γ-irradiation with single 
doses increasing from 5 to 7 Gy. (Bottom) Kaplan–Meier survival curves depending on the two variables HC dose (increasing reconstitution) and dose of γ-irradiation 
(increasing ablation). (Green lines) HCT, no infection. (Red lines), HCT and intraplantar infection with a constant dose of purified mCMV. Green- and red-shaded 
panels correspond to the bone marrow histology shown in Figures 3A,B, respectively. Reproduced from Ref. (59) with permission from Caister Academic Press, 
Norfolk, UK.
4
Reddehase Mutual Interference between Cytomegalovirus and HCT
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 294
of detachment and rounding due to cytoskeleton disruption 
(Figure 2B).
Previous work has revealed that these cells support myeloid 
lineage hematopoiesis (generation of granulocyte–monocyte 
progenitors from stem cells) in long-term BM cultures (LTBMC) 
when uninfected. In contrast, mCMV (Smith strain) infection 
of LTBMC, containing an established stroma cell monolayer, 
leads to cessation of myelopoiesis, concominant with the peak of 
virus productivity and cytopathic effect in the stromal cells (63). 
Importantly, transfer of HC from these infected LTBMC to unin-
fected stroma cell monolayers rescued myelopoiesis. This finding 
revealed a maintained myelopoietic potential of HC recovered 
from infected cultures, and thus mechanistically localized the 
inhibition of myelopoiesis, the so-called “myelosuppression,” to 
infection of the stromal cells.
These in  vitro findings for mCMV are in good accordance 
with an earlier study on hCMV by Apperley and colleagues (64) 
concluding that stromal cells, but not HC, are infected by the 
attenuated, high-passage fibroblast-adapted hCMV laboratory 
strain AD169 and, remarkably, also by four out of four tested low-
passage “clinical” isolates. As this study did not involve rescue 
of HC from infected cultures by transfer to uninfected stroma 
cell monolayers, and because latent infection of HC may have 
remained undetected by the methods available at that time, it 
was open to question if virus-exposed human HC retained their 
full myelopoietic potential. The mouse model would predict in 
retrospect that this was likely the case.
The issue of the mechanism of myelosuppression by hCMV 
was resumed by Simmons et  al. in the group of Torok-Storb 
by considering perturbation of stromal cell function versus 
direct infection of committed myeloid progenitors in human 
LTBMC (65). Testing laboratory strain AD169 in comparison 
to low-passage hCMV isolates, the authors found that 12 out 
of 20 isolates behaved like AD169 in that they failed to infect 
HC but inhibited myelopoiesis in human LTBMC associated 
with infection of stromal cells, whereas the remaining 8 isolates 
showed tropism for hematopoietic progenitors. Notably, four out 
of these eight isolates showed little tendency to infect the stromal 
cells, indicating loss of stromal cell tropism and acquisition or 
maintenance of HC tropism.
In the light of abundant evidence for latent infection of 
hematopoietic stem and/or progenitor cells by hCMV (66–70), 
it would be of interest if this really applies to all isolates of 
hCMV or if it might possibly correlate with the tropism dif-
ferences reported for the mechanisms of myelosuppression. To 
our knowledge, virus reactivated in vitro from highly purified, 
contaminant-free, latently infected HC of otherwise healthy 
volunteers has not been typed and tested for its cell tropism. 
For reactivation in vivo, that is in patients in whom hCMV has 
reactivated, it is difficult, if not impossible, to unequivocally 
identify the cellular site of the reactivation event. As low-passage 
isolates from patients with CMV disease usually result from 
recent reactivation events, and as most of those do not show 
HC tropism (see above), it is likely that they were derived from 
FiGURe 2 | infection of BM stromal cells in primary cell culture.  
(A) Images of the typically flattened, uninfected myofibroblastic BM stroma 
cells co-expressing smooth muscle cell marker α-SM-actin (a1, red 
fluorescence) and endothelial cell marker von Willebrand factor concentrated 
in Weibel–Palade bodies (a2, green fluorescence). (a3) merge. (B) Cytopathic 
effect of mCMV infection in the BM stroma cells. Detection of intranuclear E1 
protein (spotty green fluorescence) indicates that infection has proceeded to 
the early (E) phase of the viral replicative cycle. Bar markers: 10 μm. Images 
illustrate information reported in Ref. (59).
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non-HC cell types. This would also explain why the highest risk 
of reactivation in HCT recipients is associated with latent hCMV 
carriage by the recipient (R+), whereas it is associated with latent 
hCMV carriage by the donor (D+) in SOT (71). Of interest in this 
context is the finding that in a human–sheep xenograft model 
human hematopoietic stem cells (HSCs) that mediate long-term 
in vivo engraftment were not susceptible to hCMV infection (72). 
Likewise, in the mouse model, HCT performed with BM cells 
from latently infected donors failed to transmit latent mCMV 
to recipients. This finding indicated that hematopoietic stem 
and/or progenitor cells that repopulate the BM did not carry 
and multiply latent viral genome upon their proliferation and 
differentiation, whereas donor organs (lungs, liver, and spleen) 
at the same time harbored reactivation-competent latent virus 
at a high load (73).
The difference between mCMV and hCMV regarding latency 
in HC is currently interpreted as a fundamental pathobiological 
difference between the two viruses and is taken as an argument 
against the mouse model. One must consider the possibility, 
however, that hCMV variants with stroma cell tropism will not 
be detected in HC and therefore remained unreported in the past. 
Such variants are functionally more analogous to mCMV than are 
the variants with tropism for HC.
With today’s advanced knowledge of molecular and phenotypic 
hCMV strain differences, in particular in the expression of the 
virion envelope glycoprotein complexes involved in cell entry and 
thus in cell tropism, namely gH/gL/gO and gH/gL/UL128–131A, 
the latter of which is lost upon high passaging [reviewed in Ref. 
(25, 74)], it would be of interest in retrospect to relate expression 
of these complexes to tropism for HC and stromal cells. To our 
knowledge, this has not been tried yet. We consider it unlikely, 
however, that two-thirds of the low-passage isolates studied by 
the group of Torok-Storb were negative for UL128–131A ab initio 
or had lost these genes upon short-term propagation in cell cul-
ture. Importantly, whereas the designation “low passage” does not 
exclude mutations compared to the virus present in the original 
clinical sample, as it was critically discussed recently by Wilkinson 
and colleagues (25), Simmons et al. reported to have performed 
their experiments with isolates derived from clinical samples 
after just two or three passages in human foreskin fibroblasts 
(65). Although even such a short-term propagation, which is 
technically unavoidable for doing experiments, does not formally 
exclude adaptation by mutations in vitro, it appears unlikely that 
12 out of 20 independent isolates have lost HC tropism so rapidly 
in cell culture. One must consider, however, that the selection 
of mutations, as they occur in cell culture, may likewise occur 
in vivo during spread and high replication of reactivated virus in 
non-hematopoietic host tissue cells (fibrocytes, endothelial cells, 
and diverse epithelial cell types) following hematoablative treat-
ment of an HCT recipient. So, virus in “fresh” clinical samples 
likely has already undergone many rounds of replication in the 
patient during which adaptation to non-HCs in host tissues may 
have occurred unnoticed.
Like hCMV, mCMV expresses alternative gH/gL envelope 
complexes, namely gH/gL/gO and gH/gL/MCK-2 (75). As we 
have shown recently, gH/gL/gO is essential for initiating infection 
of liver macrophages, liver sinusoidal endothelial cells (LSEC), 
and hepatocytes, whereas gH/gL/MCK-2 is non-essential in the 
presence of gH/gL/gO but can substitute for missing gH/gL/gO 
in intra-tissue cell-to-cell spread as well as in the infection of 
salivary gland tissue (76).
FiGURe 3 | Bone marrow aplasia caused by infection. (A) Overview image of BM histology performed on day 14 after HCT, revealing a beginning repopulation 
of the BM of the HCT recipients with myeloid lineage colonies homing to the BM stroma in a femoral diaphysis in the absence of infection. The image corresponds 
to survival shown in Figure 1, green-shaded panel. (B) Images document absence of hematopoiesis in infected HCT recipients under conditions otherwise identical 
to those in (A), corresponding to high mortality shown in Figure 1, red-shaded panel. (b1) Overview, showing empty stromal network in a femoral epiphysis. (b2) 
Detail, with immunohistological staining of viral intranuclear protein IE1 (brown staining), detecting in situ infected, network-forming stromal cells. Bar markers: 
25 μm, throughout. Note that the size and shape of the stromal cells in situ matches their size and shape in cell culture (compare Figure 3B, b2 with Figure 2A). 
Images reproduced in rearranged form from Ref. (59, 84, 86) with permissions from Caister Academic Press, Norfolk, UK and from the Journal of Virology, American 
Society for Microbiology.
6
Reddehase Mutual Interference between Cytomegalovirus and HCT
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 294
It was recently recognized that the prototypic bacterial artifi-
cial chromosome (BAC)-cloned virus MW97.01 and viruses with 
mutations introduced into the parental BAC plasmid pSM3fr by 
site-directed mutagenesis (77–79) express a truncated variant 
of MCK-2 due to a single nucleotide deletion polymorphism 
in the coding sequence (80). As the ATCC-distributed Smith 
strain VR194, with which the murine LTBMC infections were 
performed, represents a mixture of virions with full-length and 
short MCK-2, tropism for stromal cells and missing tropism for 
HC is apparently not related to gH/gL/MCK-2 requirement for 
cell entry.
In conclusion, with regard to the mechanism of myelosup-
pression in HC culture, the mCMV model is in line with most, 
though not all, low-passage isolates of hCMV. It is therefore an 
appropriate model for hCMV strains/isolates with stromal cell 
tropism that represent the majority of isolates analyzed under this 
aspect so far (65). This must be kept in mind as a limitation of 
the current mouse models, but on the other hand, one must also 
more appreciate differences between hCMV strains/isolates that 
in some aspects exceed the differences between CMVs of different 
species.
infected BM Stroma In Situ Fails to 
Support Repopulation of BM by Low-Dose 
HCT due to Stromal Hemopoietin 
Deficiency
As discussed above, “cell culture only” experiments should 
preferably be performed with the human pathogen, except to 
show equivalence of results between human pathogen and model 
pathogen, hCMV and mCMV in the here discussed case, for 
subsequent experimental in  vivo studies in the animal model. 
Any animal “model” for human disease should be approximated 
to the clinical correlate and get its legitimation by experimental 
in vivo approaches to clinical questions that cannot be answered 
by observational clinical studies. The mouse model of experimen-
tal infection of immunocompromised HCT recipients provided 
“proof of principle” for HC graft failure due to a functional defi-
ciency of infected BM stroma in providing the essential micro-
enviromental support for HC homing, HSC self-renewal, and 
hematopoietic lineage differentiation (81–86). Under conditions 
of a sublethal degree of hematoablative treatment and low-dose 
HCT, most mice survive in the absence of infection but die if 
infected (Figure 1, shaded survival plots), which clearly shows 
the viral etiology of mortality in such a setting.
Histological images in these groups revealed BM-repopulating 
hematopoietic colonies, including myelomonocytic and erythroid 
sublineage colonies of the myeloid lineage (86), in the absence of 
infection compared to complete BM aplasia in the presence of 
infection (Figures 3A,B, b1, respectively). It should be noted that 
BM aplasia is also reflected by a pancytopenia, including throm-
bocytopenia, in the blood, and by petechial bleedings. This situ-
ation is reminiscent of thrombocytopenic purpura in newborns 
with congenital CMV disease (8, 18). Network-forming stromal 
cells are infected in the BM, as shown by immunohistochemical 
(IHC) staining for intranuclear IE1 protein, though the stromal 
network does not seem to be texturally disrupted (Figure  3B, 
b2). In accordance with these findings, stromal gene expression 
included transcripts for viral regulatory protein m123/IE1 and 
the late envelope glycoprotein M55/gB, thus confirming stromal 
infection (84). Very sensitive detection of infectivity in infected 
BM by a cell culture assay for IE1 gene expression (RT-PCR) 
transferable to permissive mouse embryo fibroblasts as indicator 
cells revealed a low-level productive infection of BM stroma (86). 
In both parameters, IE1 transcripts and infectivity, stromal infec-
tion was not notably reduced by HCTs performed with increasing 
numbers of transplanted HC (86), which indicated that trans-
planted HC do not exert a stroma-protective, innate antiviral 
FiGURe 4 | infection inhibits HC engraftment. (A) Sketch of the 
experimental design of transplanting male (XY, gene sry+) HC to female (XX, 
gene sry−) BALB/c recipients, resulting in transplantation chimeras with sry+ 
HC and sry− stromal cells. Flash symbol: total-body γ-irradiation (B) PCR 
quantitation of sry+ HC engraftment on day 14 after HCT without infection (Ø) 
or with infection (CMV). Modified from Ref. (86) with permission from the 
Journal of Virology, American Society for Microbiology.
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function. Unaltered levels of transcripts from cellular house-
keeping genes pthrp and β-actin reflected comparable numbers 
of stromal cells in both groups in accordance with the virtually 
intact stromal network (84). Notably, however, transcripts for the 
hemopoietins stem cell factor (SCF, also known as Kit-ligand or 
Steel factor), granulocyte colony-stimulating factor (G-CSF), and 
interleukin-6 (IL-6) were significantly reduced upon infection of 
BM stroma (84–86).
As stromal cytokines operate as growth and differentiation 
factors for HSCs and lineage-committed progenitor cells [for a 
review, see Ref. (87)], this functional deficiency of the stroma can 
explain the reduced hematopoiesis. It should be noted that these 
early studies on hemopoietin gene expression were not compre-
hensive, and revisiting this issue with differential high-density 
microarray analyses likely will reveal more alterations in stromal 
gene expression relevant to the hematopoiesis-supporting func-
tion of BM stroma, possibly also beyond known hemopoietins.
High-Dose HCT enables Partial BM 
Repopulation Sufficient for Surviving 
infection
The survival plots (Figure 1) made evident that mCMV infection 
in experimental HCT settings is not inevitably lethal but that 
mortality can be prevented by high-dose HCT performed with 
a sufficiently high number of transplanted HC, and thus of HSC. 
Long-term survival implied a successful repopulation of BM and 
control of the infection. It remained open to question, however, 
if BM stroma pathogenesis of mCMV is prevented by high-dose 
HCT or is still operative, though with an incomplete inhibition 
of hematopoiesis. The latter possibility proved to be correct in an 
approach of transplanting graded numbers of male (XY) geno-
type sry+ donor HC into female (XX) genotype sry− recipients, 
thus generating chimeras with sry+ HC and sry− stromal cells 
(Figure 4A) (86).
For a better understanding of this approach, it is important to 
recall that BM stromal cells present in the donor BM cell popula-
tion are not transplantable under conditions of HCT and thus 
do not home to the recipient’s BM compartment [reviewed in 
Ref. (62)]. We have experimentally reconfirmed this previously 
by a serial transplantation of female donor BM cells into male 
recipients, leading to chimeras with sry− HC and sry+ stromal 
cells, followed by transplantation of the chimera-derived BM cell 
population into female sry− secondary recipients. The sry gene of 
the chimeras’ stromal cells was not detectable by sensitive PCR in 
the BM of the secondary recipients (84).
Quantitation of BM-repopulating sry+ HC in the XY–XX 
chimeras by sry gene-specific PCR revealed a low level of BM 
repopulation by HCT performed with 10,000 HC, and its 
mortality-associated extinction by mCMV infection (Figure 4B). 
Importantly, although increasing doses of transplanted HC led 
to detectable progeny repopulating the BM to an increasing 
degree even after mCMV infection, an inhibition became appar-
ent for all tested doses, as indicated by parallel log–log linear 
input-versus-output graphs (86). Note that repopulation based 
on 105 donor HC was not sufficient for survival in the presence 
of infection, whereas repopulation based on 106 or more donor 
HC led to increasing survival rates (compare repopulation data 
in Figure 4B with survival rates in Figure 1).
Notably, the initial stromal damage set by the acute infection 
of HCT recipients was not repaired after clearance of produc-
tive infection and instead led to a lasting reduction (observation 
periods of 1, 3, and 6  months) in the number of HSC capable 
of self-renewal and long-term BM repopulation (82, 83). This 
was shown by a limiting dilution quantitation of HSC present 
in the BM of uninfected compared to infected primary HCT 
recipients by serial transfer of their HC in graded numbers into 
uninfected secondary HCT recipients, followed 6 weeks later by 
monitoring of BM repopulation by donor HC (for a sketch of 
the experimental regimen, see Figure  5A). Specifically, when 
HC were derived from latently infected compared to uninfected 
FiGURe 5 | Sketch of serial transplantation and re-transplantation protocols. (A) Serial transplantation of HC for quantitating BM-repopulating hematopoietic 
stem cells (HSC) depending on a past productive infection of primary HCT recipients. Infected primary HCT recipients become lastingly deficient in hematopoiesis 
reflected by reduced numbers of HSC. (B) Localization of the cause of enduring hematopoietic deficiency in primary HCT recipients with a past productive infection. 
Failure to cure by re-transplantation with normal HC localizes the hematopoietic deficiency to the BM stroma. This Figure illustrates the experimental regimens used 
to demonstrate enduring bone marrow stroma deficiency reported in Ref. (82, 83).
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primary HCT recipients as donors for serial transfer, five-times 
more HC, and thus HSC, were needed to long-term repopulate 
the BM of uninfected secondary HCT recipients. Notably, this 
lastingly reduced HSC frequency in the BM of latently infected 
primary HCT recipients was not caused by a latent infection of 
HC/HSC, as one might have surmised, but could be attributed 
to an irreversible deficiency in stromal function, as it was not 
cured by re-transplantation with fully functional HC from 
untreated, normal donors (83) (Figure 5B). Altogether, although 
high-dose HCT allows BM repopulation sufficient for a level of 
hematopoietic reconstitution that prevents lethal CMV disease, 
latently infected HCT recipients remain lastingly deficient in 
their stromal function and in their transplantable hematopoietic 
potential.
Bone marrow repopulation after high-dose HCT in the 
absence of stroma repair clamors for an explanation: if 
hemopoietin expression is so in deficit that it fails to support 
few HSC transferred by low-dose HCT, how can it then sup-
port a higher number of HSC transferred by high-dose HCT? 
An explanation is provided by the model of “hematopoietic 
niches” (Figure 6). The existence of a BM niche, the location 
in BM stroma in which an HSC resides, was proposed in 
the end 1970s (88) and is still highly topical as indicated by 
several very recent review articles (89–92). In essence, a niche 
is defined as a microanatomical site, formed by BM stroma, 
which provides the physical environment and locally delivered 
hemopoietins for HSC lodging, self-renewal, and lineage dif-
ferentiation. Important in view of reduced SCF gene expres-
sion upon stromal infection (see above) is the finding that the 
transmembrane-bound form of SCF, the tmSCF, is a critical 
hemopoietin in HSC lodgment (93). Accordingly, what counts 
is the local stromal support of HSC in the niche, rather than 
systemic hemopoietin levels. To explain our findings, we can 
therefore propose that partial infection of BM stroma “closes” 
a proportion of the niches, while other niches remain “open.” 
Upon low-dose HCT, the few HSC mostly meet “closed niches” 
with a low chance to lodge to an “open niche,” whereas the like-
lihood for occupying “open niches” increases with the number 
of transplanted HSC despite an unaltered rate of stroma cell 
infection (Figure 6).
CMv-Mediated Hematopoietic Deficiency 
Leads to Reduced Reconstitution of CD8+ 
T Cells
As T lymphopoiesis is based on progenitors in the BM, hemat-
opoiesis reduced by stromal deficiency should also impact on 
downstream T-cell reconstitution. As clinical data have correlated 
control of infection with the reconstitution of CD8+ T cells (94, 
95), we monitored reconstitution of donor-type CD8+ T cells in 
uninfected compared to infected, sublethally irradiated, HCT 
recipients depending on the number of transplanted donor HC 
in an MHC-I disparate HCT model (Figure  7). In this model, 
the MHC class-I (MHC-I) molecule H-2Ld expressed on donor 
(BALB/c: KdDdLd) HC serves as a cytofluorometric marker for 
donor-type reconstitution of genetically Ld-negative recipients 
(BALB/c-H-2dm2: KdDd) in which a graft-versus-host reaction 
to MHC-I is excluded by antigenic match and a host-versus-
graft reaction to Ld expressed by the donor cells is avoided by 
transplantation tolerance. T cells reappear in the spleen in the 
third week after HCT. Based on a component contributed by 
radiation-resistant thymic T-cell precursors, a chimerism with 
donor-type (Ld-positive) and recipient-type (Ld-negative) CD8+ 
T cells is established in the splenic T-cell population. As expected, 
increasing doses of transplanted donor HC shift the chimeric 
balance to the donor side in uninfected HCT recipients. Notably, 
this “donor shift” required more donor HC when recipients were 
infected (96).
FiGURe 7 | infection of HCT recipients impedes the reconstitution of 
CD8+ T cells. (Top) Sketch of the experimental protocol, transplanting HC 
from BALB/c mice to immunocompromised (flash symbol: sublethal 
γ-irradiation with a dose of 6 Gy) mutant mice not expressing the MHC-I 
molecule Ld. (Bottom) Cytofluorometric analysis of Ld expression in the 
recipients revealed chimerism within the spleen-derived CD8+ T-cell 
population that shifted toward donor-type reconstitution with increasing 
doses of transplanted HC (left panel, HCT). This shift is impeded by infection 
(right panel, HCT + infection). *100% mortality. Percentages of donor-derived 
CD8+ T cells are indicated. Modified from Ref. (96) with permission from the 
Journal of Virology, American Society for Microbiology.
FiGURe 6 | Model of “closed” and “open” hematopoietic niches. (Left) 
Low-dose HCT: in the model example, a single transplanted HSC has a 20% 
chance to occupy a single “open niche” (green) out of a total of five niches of 
which four are closed (red) due to CMV infection of the BM stromal cells that 
form the niche. (Right) High-dose HCT: high probability of occupying the 
single “open niche” out of five niches when five HSC are transferred. Note 
that the probability for a successful lodging event is <100% since more than 
one HSC may try to lodge to a “closed niche,” but the overall probability for 
the event that at least one out of five transplanted HSC lodges to the single 
“open niche” is increased. Importantly, the rate of stroma cell infection is not 
notably influenced by the dose of transplanted HC over the range tested. 
Stop symbol: hematopoiesis is not supported. Bent arrow: successful HSC 
lodging and self-renewal. This Figure provides a graphical new explanation 
for data published in Ref. (86), corresponding to Figure 4B.
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In conclusion, by infecting BM stroma, CMV infection 
interferes with the reconstitution of donor-derived CD8+ T cells. 
In can be proposed that by inhibition of the reconstitution of 
virus-specific CD8+ T cells, CMV enhances BM pathogenesis in 
a feed-back loop, resulting in a less efficient antiviral control and 
thus a prolonged virus replication, bearing a risk of CMV organ 
disease.
iNTeRFeReNCe OF T-CeLL 
ReCONSTiTUTiON wiTH CMv  
iNFeCTiON AFTeR HCT
Reconstitution of Antiviral CD8+ T Cells is 
essential for Controlling CMv infection 
after HCT
Early immunomonitoring studies in HCT patients indicated 
that control of reactivated hCMV infection correlates with the 
reconstitution of antiviral CD8+ T cells (94, 95), and subsequent 
adoptive cell transfer studies in the mouse model (see above) 
as well as in clinical trials (see above) confirmed a protective 
antiviral function of primed CD8+ effector and/or memory T 
cells. It was therefore reasonable to propose that reconstitution 
of CD8+ T cells after high-dose HCT is the critical parameter for 
the control of CMV infection and survival.
On the other hand, mCMV infection models for experimental 
conditions other than HCT have shown that CD8+ T cells are not 
indispensable for controlling the infection. Specifically, long-term 
CD8+ (CD8+ T cells and CD8+DC)-depleted but otherwise 
immunocompetent mice (97) as well as β2m knock-out mice 
deficient in mature cell surface MHC-I and thus also deficient in 
CD8+ T cells (98) control virus replication in all organs, includ-
ing salivary glands, by alternative antiviral effector mechanisms 
involving CD4+ T cells and innate immune functions. In a more 
recent study comparing mCMV infection control in TCR α/β 
and/or γ/δ deficient mice, it was concluded that γ/δ T cells are as 
competent as α/β T cells in protecting mice from CMV-induced 
death (99). It is important to recall that alternative mechanisms 
did not develop after short-term CD8 depletion, suggesting that a 
remodeling of immune homeostasis to functionally substitute for 
CD8+ T cells needs time. Dispensability of CD8+ T cells was also 
suggested by cell transfer models showing that NK cells (100), 
memory B cells (101), effector CD4+ T cells (102) as well as γ/δ T 
cells (99, 103) can, in principle, confer protection against mCMV 
infection.
However, the HCT model gave us a lesson on how careful one 
must be with extrapolating mechanisms of antiviral control from 
one experimental setting to another. Unlike the situation in long-
term CD8+ T cell-depleted or genetically CD8+ T cell-deficient 
mice, in which an altered immune homeostasis, not involving 
CD8+ T cells, has time to develop, reconstitution in HCT patients 
must rapidly provide antiviral effector cells to come in time for 
preventing viral spread that otherwise would lead to lethal viral 
pathogenesis.
For studying a scenario designed as a model that more closely 
approximates a clinical correlate, we focused our investigation 
FiGURe 8 | CD8+ T-cell infiltration of infected lungs after HCT 
coincides with control of the infection in nodular inflammatory foci 
(NiF). HCT was performed with the high dose of 107 HC, a condition under 
which infected recipients survive (recall Figure 1). (A) Coincidence of the 
peak of CD8+ T-cell infiltration (top panel) and the onset of decline in titers of 
infectious virus (bottom panel). Symbols represent data from individual mice 
with the median values marked. Reproduced from Ref. (59, 109) with 
permissions from Caister Academic Press, Norfolk, UK and from the Journal 
of Virology, American Society for Microbiology. (B) Confinement of pulmonary 
infection in NIF; shown here is a NIF with peribronchiolar localization. 
Two-color IHC with red-staining of IE1 protein in infected lung cells and black 
staining of T cells. The bar marker represents 25 μm. This image has been 
the cover photograph of Journal of Virology, volume 74, issue no. 16 (August 
2000), accompanying the publication cited here as Ref. (61). Reproduced 
with permission from the American Society for Microbiology.
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in the mouse model on the infection of the lungs after HCT, 
as interstitial pneumonia (CMV-IP) is the most critical organ 
manifestation of CMV disease in HCT patients [reviewed in Ref. 
(104, 105)]. As revealed by the mouse model, lungs are not only 
a major target organ of viral pathogenesis (26, 61, 106–109) but 
also a site of virus latency and reactivation (110) as well as of 
“memory inflation” during latency [reviewed in Ref. (48, 49)].
Compared to uninfected HCT recipients, lungs of infected 
HCT recipients showed massive leukocyte infiltration, notably 
including granulocytes, and widened alveolar septae (109). 
Infected cells in the lungs include endothelial cells of pulmonary 
capillaries, interstitial fibrocytes, pneumocytes of the alveolar 
epithelium, and alveolar macrophages. CD8+ T cells dominated 
the T-cell infiltrates in infected HCT recipients, and their peak 
of infiltration at 4  weeks after HCT coincided with the begin-
ning decline in virus titers (Figure 8A). Instant ex vivo cytolytic 
activity of pulmonary infiltrate cells, not requiring in vitro res-
timulation, was mediated by TCRα/β+CD3+CD8+ T cells, but not 
by TCRα/β+CD3+CD4+ T cells or TCRγ/δ+CD3+ T cells (109), 
and cytolytically active TCRα/β+CD3+CD8+ T cells recovered 
from pulmonary infiltrates protected against CMV pathogenesis 
upon adoptive cell transfer (61, 96). The ex vivo cytolytic activity 
was completely inhibited by CMA (folimycin, concanamycin A) 
(109), known to selectively block the perforin-based pathway 
of cytolysis (111). More recent work has determined the pre-
dominant phenotype of the pulmonary infiltrate CD8+ T cells as 
CD62LlowKLRG1high (112), a phenotype attributed to short-lived 
effector cells, SLECs (113).
Typically, tissue-infiltrating CD8+ CTL are attracted toward 
infected tissue cells to form nodular inflammatory foci (NIF) 
(Figure  8B) (57, 61, 96, 114–116). NIF are microanatomical 
structures in which the infection is confined and eventually 
resolved; thus, NIF formation is indicative of antiviral control 
and protection. Importantly, NIF formation by tissue-infiltrating 
CTL requires the presentation of cognate epitopes on the infected 
tissue cells. This has been shown by transfer of cells from epitope-
specific CTL lines (CTLL) and infection with viruses in which the 
C-terminal amino acid residue of the respective antigenic peptide 
(mostly a nonapeptide) is mutated to Ala, mutations X9Ala, a 
strategy known to largely reduce peptide processing at the steps 
of proteasomal cleavage, precursor peptide transport into the ER, 
and MHC-I binding (117). While the transferred CTLL formed 
NIF and protected against wild-type virus infection, the same 
cells did not arrange into NIF and failed to protect against X9Ala 
mutant viruses (57, 114).
Although all this information strongly indicated a dominant 
role for CD8+ T cells in controlling CMV infection in the phase 
of reconstitution after HCT, it remained open to question if they 
are essential or if antiviral control is secured by redundance. 
Thus, analogous to what was found in the other models discussed 
above, alternative effector mechanisms might take over in case 
absence of CD8+ T cells leads to an altered immunoregulation 
and homeostasis. This possibility was tested by depleting T-cell 
subsets in infected HCT recipients on days 7 and 14 of an ongo-
ing reconstitution. The result was unequivocal in that mortality 
invariably was 100% when HCT recipients were depleted of 
CD8+ T cells in the course of reconstitution, whereas almost 
all recipients survived infection after depletion of CD4+ T cells 
(Figure  9) (60, 61). Thus, in the specific case of an ongoing 
reconstitution after HCT, CD8+ T cells are not replaceable in 
their function with any other adaptive or innate immune cell 
FiGURe 10 | CD8+ T cells are essential for confining the infection to 
nodular inflammatory foci (NiF) during reconstitution after HCT. 
Two-color IHC images of viral pathology in the liver correspond to the 
survival/mortality data shown in Figure 9. (A) Uncontrolled virus spread in 
liver tissue after HCT and depletion of CD8+ T cells. The red arrow 
representatively points to an infected hepatocyte identified by red-staining of 
intranuclear IE1 protein. The black arrow representatively points to an 
infiltrating CD4+ T cell identified by black staining of cell surface CD3ε. Note 
that the CD4+ T cells are randomly distributed, do not form NIF, and 
apparently fail to limit the virus spread. (B) Lack of liver tissue infiltration, 
absence of NIF, and uncontrolled spread of the infection after depletion of 
both T-cell subsets, which excludes participation of other CD3ε-expressing 
immune cells, such as γ/δ T cells and NKT cells, in the control of infection. As 
the infection is not controlled, cells of innate immunity (unstained) apparently 
are also not functional in antiviral protection after HCT. (C) Confinement of 
infection to NIF in the absence of T-cell depletion. (D) Confinement of 
infection to NIF is maintained after depletion of CD4+ T cells, indicating that 
formation of NIF and control of the infection by CD8+ T cells do not critically 
require CD4+ T cell help. Bar markers represent 25 μm. Reproduced in 
rearranged form from Ref. (59) with permission from Caister Academic Press, 
Norfolk, UK.
FiGURe 9 | Survival of infected HCT recipients depends on the 
reconstitution of CD8+ T cells. In the process of an ongoing reconstitution 
after HCT, T-cell subsets were depleted on days 7 and 14. Shown are 
Kaplan–Meier survival curves that reveal 100% mortality only when CD8+ T 
cells were depleted. Reproduced from Ref. (59, 61) with permissions from 
Caister Academic Press, Norfolk, UK and from the Journal of Virology, 
American Society for Microbiology.
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type. This finding is of medical relevance, as it gives a warning 
against treating GvHD after allogeneic (minor histocompatibility 
antigen-disparate) HCT by depleting T cells in case of a simulta-
neous CMV infection.
As a histopathological correlate of mortality in the absence 
of CD8+ T cells, virus spreads uncontrolled in tissues, resulting 
in extended tissue damage [for the liver, see Figure 10; for the 
lungs and further organs, see Ref. (60, 61)]. Notably, the CD4+ T 
cells infiltrate infected liver tissue, but are distributed randomly, 
not forming protective NIF (Figure  10A). After depletion 
of both T-cell subsets, random and focal T-cell infiltrates are 
both missing and, accordingly, infection spreads uncontrolled 
(Figure 10B). As the IHC staining detected the CD3ε molecule 
of TCR–CD3 complexes, absence of stained infiltrates excluded 
a participation of γ/δ T cells as well as of NKT cells, both of 
which express CD3ε. Possibly present, though unstained, innate 
immune cells apparently failed to control the infection and were 
therefore not further considered. In contrast, in the absence of 
T-cell depletion, NIF are formed and infection is confined to few 
infected cells trapped in the center of NIF (Figure 10C). As NIF 
are also formed after depletion of CD4+ T cells (Figure 10D), 
CD8+ T cells obviously form the NIF and neither depend on 
CD4+ T-cell help nor on any other CD4+ cell type, for NIF 
formation and antiviral protection. As one may argue that CD8 
depletion also depletes the CD8+ subset of DC, it is important 
to note that CD8+ T cells recovered from infected lungs and 
purified by cell sorting protected adoptive transfer recipients 
as a final proof of their direct antiviral effector function in vivo 
(61, 96).
In conclusion, in the HCT model of CMV infection, 
reconstitution of CD8+ T cells is the most critical parameter 
for the control of posttransplantation CMV infection. Thus, 
importantly, experimental HCT in the mouse model provided 
experimental “proof of principle” for the observational clinical 
evidence of CMV control by reconstituted CD8+ T cells. It 
should be emphasized that we have discussed here the resolu-
tion of acute organ infection required for preventing lethal 
CMV disease in HCT recipients. From a medical point of view, 
this immediate antiviral function is important for the patient 
in the first place. Notably, the above discussed HLA-transgenic 
mouse model of immunotherapy by adoptive cell transfer has 
revealed a benefit from adoptive cotransfer of TCR-transduced 
human CD4+ T cells in the control of antigenically “humanized” 
mCMV by TCR-transduced human CD8+ T cells (57). On the 
long run, CD4+ T cells reconstituted by HCT likely play a part 
in the long-term maintenance of protective CD8+ T cells and 
provide help for CD8+ T cell “memory inflation” during viral 
latency (118).
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A Novel Aspect in CMv Control: Mast 
Cells enhance Protective Tissue 
infiltration
Recent data in an immunocompetent mouse model have identified 
mast cells (MC) as a previously unconsidered player in the control 
of pulmonary CMV infection (116, 119, 120). The bottom-line 
message from these studies is that mCMV productively infects 
MC, causing their degranulation and release of the chemokine 
CCL5 (RANTES), which recruits antiviral CD8+ T cells to 
infected lungs where they transmigrate the capillary endothe-
lium by diapedesis and form protective NIF within infected lung 
interstitium and parenchyma. Thus, in a negative feed-back loop, 
mCMV contributes to its own immune surveillance. Work in 
progress aims at demonstrating this function of MC also in the 
HCT model, and if so, a question will be whether enhanced CD8+ 
T-cell recruitment depends on radiation-resistant, tissue-resident 
MC of the recipient or on the reconstitution by donor MC derived 
from transplanted hematopoietic progenitors. It is postulated that 
enhanced recruitment of antiviral CD8+ T cells to infected lung 
tissue by MC-derived CCL5 compensates, at least in part, for the 
overall reduced hematopoietic reconstitution of CD8+ T cells and 
thereby contributes to the prevention, or at least moderation, of 
CMV pathology.
Limited importance of viral epitope 
immunodominance for Control of Acute 
infection
In any individual, only few viral CD8+ T-cell epitopes, that is 
virus-encoded antigenic peptides presented by host MHC-I 
molecules as peptide–MHC-I (pMHC-I) complexes, elicit a 
quantitatively dominant response. “Immunodominant epitopes” 
(IDEs) differ between human individuals (56) and between 
different mouse strains (30, 121), reflecting MHC-I polymor-
phism on the host population level. Immunodominance can, 
in theory, be determined by the primary “pre-immune” T-cell 
repertoire, including its spectrum of TCR affinity/avidity 
to pMHC-I and TCR expression density, by the efficiency of 
peptide processing and presentation in antigen-presenting cells 
(APCs), and by the extent of clonal expansion. Interestingly, 
the primary TCR repertoire can be variable even in genetically 
identical mice due to epigenetic differences, such as stochastic-
ity in the TCR gene rearrangement [discussed and reviewed in 
Ref. (122–125)].
These parameters are linked in that clonal expansion depends 
on signaling intensity, which is defined not only by the affinity/
avidity of TCR-pMHC-I interaction at the immunological syn-
apse during the first contact with one professional APC but also 
on the probability of repeated subsequent antigen encounters 
with professional and/or non-professional APCs. Competition 
for growth factors, such as IL-2, is likely involved in clonal expan-
sion and competition between clones. It is not an independent, 
T cell-intrinsic contributor, however, because clonotypic differ-
ences in IL-receptor expression levels cannot easily explain the 
epitope-specificity. Rather, epitope-specific enhanced signaling 
can upregulate the expression of IL receptors and thereby convey 
a growth advantage.
From these theoretical considerations one would have pre-
dicted that clones with high-avidity TCR–pMHC-I interactions 
gain a growth advantage, which would explain their “immuno-
dominance” in quantity. Strikingly, the opposite appears to be 
the case. Relating the frequency of viral epitope-specific CD8+ 
T cells to their functional avidity, tested by an IFN-γ ELISpot 
assay with stimulator cells exogenously loaded with antigenic 
peptide at decreasing concentrations, response hierarchies to 
epitopes changed with the avidity threshold defined by peptide 
concentration. Specifically, at limiting peptide concentrations, 
the two most prominent IDEs of mCMV in BALB/c (H-2d) mice, 
namely m123/IE1 and m164, were no longer immunodominant 
(126). Thus, “immunodominance” reflects high numbers of 
low-avidity clones, whereas protection against infection is medi-
ated by high-avidity clones (30, 127) capable of recognizing low 
numbers of pMHC-I complexes formed in  vivo with limited 
amounts of naturally processed peptides. In addition, cell surface 
presentation of recently loaded pMHC-I complexes is limited by 
the action of viral immune evasion proteins that inhibit their cell 
surface trafficking [(128), reviewed in Ref. (129)].
It is conspicuous that IE genes are a coding hot spot for CD8+ 
T-cell immunogenicity of mCMV, confirmed more recently 
also for hCMV (see above). Interestingly, an immunodominant 
mCMV epitope, originally assigned to the early (E) phase protein 
m164/gp36.5 (130, 131), was recently shown to be also expressed 
in the IE phase from an upstream IE transcript (132). An expla-
nation might be that the expression of IE genes, by definition, 
precedes the expression of downstream viral genes, including 
most of the viral immune evasion genes (18), thus providing a 
temporal advantage for T-cell priming with the consequence of IL 
consumption. In addition, cell type-dependent intrinsic host cell 
defense mechanisms and antiviral cytokines of the innate immune 
response might restrict in  vivo gene expression in APCs to IE 
genes, and this could convey a selection advantage to CD8+ T cells 
specific for IE peptides. Sporadic episodes of IE gene expression 
during viral latency, associated with repetitive restimulation of 
cognate tissue-patrolling T celIs, drive “memory inflation” and 
thereby contribute to the high frequency of IE-specific CD8+ 
effector-memory T cells observed in latently infected tissues 
[reviewed in Ref. (48, 49)].
It is an underappreciated aspect that proteomic differences 
between virus strains also can determine the repertoire of IDEs 
by antigenicity-loss and antigenicity-gain mutations. In the 
BALB/c (H-2d) mouse model, four antigenic peptides (M105, 
m123/IE1, m145, and m164) have been classified as IDEs based 
on the response magnitude in the primary CD8+ T-cell response 
to acute mCMV infection (133). Notably, however, as shown by 
genetic deletion of all four of these IDEs, they are not essential for 
antiviral control in adoptive immunotherapy (133) and during 
reconstitution after HCT (117).
implications for a Preemptive 
Cytoimmunotherapy of CMv infection 
after HCT
As T lymphopoietic reconstitution of antiviral CD8+ T cells 
following HCT takes time – too much time in cases of an early 
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CMV reactivation  –  it makes sense to bridge the “window of 
risk” between HCT and reappearance of CD8+ T cells by adop-
tive transfer of virus-specific CD8+ effector or memory cells. 
Combining HCT with cytoimmunotherapy in the mouse model 
has indeed revealed a faster resolution of productive organ infec-
tion and an improved survival rate. In addition, long-term survi-
vors of the combination therapy established latent infection with 
a lower viral genome load and, in consequence, a lower incidence 
of virus recurrence upon a second hemato-/immunoablation 
(134). Benefit from the combination therapy was confirmed in 
the meantime by clinical investigation (see above), except that, of 
course, the mouse model’s prediction of a reduced risk of second-
ary virus recurrence cannot be easily verified in patients.
As previous data in the mouse model have revealed a much 
higher protective efficacy of memory cells compared to effector 
cells of a CTLL with the very same viral epitope-specificity (114, 
135), transfer of memory cells is preferable. Early data in the 
mouse model have revealed that an early intervention (preemp-
tive cell transfer) is much more efficient than a later intervention 
when virus spread in tissues has already proceeded (therapeutic 
cell transfer) (26, 27). Prophylactic cell transfer with no preceding 
diagnosis of virus reactivation makes less sense, as virus reactiva-
tion is a stochastic event (136), which implies that the time of 
reactivation – and if it reactivates at all – is not predictable. Like 
with antiviral drugs, close PCR monitoring for CMV in the blood 
to start “preemptive” therapy upon first evidence for reactivation 
is currently the strategy of choice.
“Individualized medicine” in cytoimmunotherapy would 
require not only HLA typing, which is done anyway for HCT, 
but also knowledge of the epitopes encoded by the virus strain(s) 
harbored by latently infected CMV “seropositive” donors and 
recipients. As the reactivating CMV strain(s) are usually not 
known in advance and are rarely isolated and sequenced, CD8+ 
cytoimmunotherapy should not rely on a single viral epitope 
FiGURe 11 | Synopsis of the mutual interference between Cytomegalovirus and reconstitution of protective immunity after HCT. See the body of the 
text for explanation. HC, hematopoietic cells; MC, mast cells; SCF, stem cell factor; G-CSF, granulocyte colony-stimulating factor; IL-6, interleukin-6; NIF, nodular 
inflammatory focus/foci. Red TCR symbol: CMV-specific. Blue TCR symbol: unrelated TCR specificity. Red-colored nuclei: infected cells.
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T-cell therapy is to avoid the viral pathogenesis not only in organs 
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progress to evaluate this prospect.
CONCLUDiNG SiMPLiFieD view OF CMv 
iNFeCTiON CONTROL AFTeR HCT
As a synopsis, the mutual interference between CMV and 
CD8+ T-cell reconstitution after HCT is sketched in Figure 11. 
In essence, by infection of BM stromal cells, the expression 
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